INTRODUCING
AGALSIDASE BETA
A multidisciplinary approach to treatment of Fabry disease is recommended.
Agalsidase beta is an intravenous enzyme replacement therapy for patients with Fabry disease.1 The mechanism of action of agalsidase beta is presented in Figure 1. The availability of agalsidase beta differs between countries. For further information, please consult your local prescribing information.
Figure 1.
Mechanism of action of agalsidase beta.1,2
C-ANPROM/INT/FAB/0017; Date of preparation: March 2021
- Sanofi Genzyme. Fabrazyme® EU Summary of Product Characteristics. Last updated November 2020.
- Ferraz MJ, Kallemeijn WW, Mirzaian M, et al. Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses. Biochim Biophys Acta 2014; 1841: 811-825.
DISEASE MANAGEMENT
Agalsidase alfa
What is agalsidase alfa?
Agalsidase alfa is an intravenous enzyme replacement therapy for patients with Fabry disease.
DISEASE MANAGEMENT
Enzyme replacement therapy
What are the enzyme replacement therapies for Fabry disease?
Two long-term enzyme replacement therapies are available for patients with Fabry disease: agalsidase alfa and agalsidase beta.
DISEASE MANAGEMENT
Chaperone therapy
What are the chaperone therapies for Fabry disease?
One oral chaperone therapy, migalastat, is available for patients diagnosed with Fabry disease and who have an amenable variant.
Register
Registration gives the benefit of site update emails and additional information on new education materials and events